Traditionally, the concluding presentation of the plenary session is given by Prof. Kappos, who presents an overview of the recent advances in the treatment of MS. In the last year, promising data on new compounds to treat relapsing-remitting MS (RRMS) and, for the first time, progressive MS, were presented and published. The progress made in treating MS is based on the identification of appropriate drug targets through the interaction of basic and clinical research. With increasing understanding of the disease course of MS, more sensitive and accurate measures of treatment efficacy are developed, and innovative trial designs integrate the knowledge from previous studies. Since the last State of the Art Symposium, two compounds were approved by the health authorities. The novel treatment options include Glatiramyl®, a new formulation of glatiramer acetate, and daclizumab (Zinbryta®). Further therapeutics are expected to become available in the coming months.

See All 19th State Of The Art Symposium Videos